Clinical Research Directory
Browse clinical research sites, groups, and studies.
Tirzepatide Following Adrenalectomy in Mild Autonomous Cortisol Secretion
Sponsor: Alaa Sada
Summary
Mild Autonomous Cortisol Secretion (MACS) is a condition in which an adrenal gland produces excess cortisol and is associated with high blood pressure, diabetes, and weight gain. Surgical removal of the adrenal gland (adrenalectomy) is standard treatment, but some patients continue to have metabolic health problems after surgery. This randomized study will evaluate whether treatment with tirzepatide after adrenalectomy improves metabolic outcomes in patients with MACS compared with adrenalectomy alone.
Official title: A Randomized Clinical Trial of Tirzepatide Following Adrenalectomy in Mild Autonomous Cortisol Secretion
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
34
Start Date
2026-07-27
Completion Date
2028-12-31
Last Updated
2026-07-30
Healthy Volunteers
No
Interventions
Tirzepatide
Tirzepatide will be initiated at the lowest dose of 2.5 mg once weekly for 4 weeks. The dose will then be titrated every 4 weeks based on patient tolerance to 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg.
Standard medical treatment
Participants will receive postoperative care and follow up per institutional standard-of-care practices
Locations (1)
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, United States